amlodipine has been researched along with Thalassemia in 4 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Thalassemia: A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 9.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| " Amlodipine, L-type calcium channel blocker with regular chelation therapy may reduce myocardial iron overload." | 5.51 | Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial. ( Aggarwal, P; Agrawal, V; Gupta, V; Kumar, I; Raj, V, 2022) |
| "Our meta-analysis found that amlodipine significantly increases cardiac T2* and decreases MIC, hence decreasing the incidence of cardiomyopathy-related iron overload in thalassemia patients." | 5.41 | Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis. ( Abdelaziz, A; Abdelwahab, OA; Amer, BE; Badawy, MM; Diab, RA; Elsharkawy, A; Goudy, YM; Mouffokes, A; Soliman, Y, 2023) |
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 5.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, V | 1 |
| Kumar, I | 1 |
| Raj, V | 1 |
| Aggarwal, P | 1 |
| Agrawal, V | 1 |
| Soliman, Y | 1 |
| Abdelaziz, A | 1 |
| Mouffokes, A | 1 |
| Amer, BE | 1 |
| Goudy, YM | 1 |
| Abdelwahab, OA | 1 |
| Badawy, MM | 1 |
| Diab, RA | 1 |
| Elsharkawy, A | 1 |
| Elfaituri, MK | 1 |
| Ghozy, S | 1 |
| Ebied, A | 1 |
| Morra, ME | 1 |
| Hassan, OG | 1 |
| Alhusseiny, A | 1 |
| Abbas, AS | 1 |
| Sherif, NA | 1 |
| Fernandes, JL | 1 |
| Huy, NT | 1 |
| Shakoor, A | 1 |
| Zahoor, M | 1 |
| Sadaf, A | 1 |
| Alvi, N | 1 |
| Fadoo, Z | 1 |
| Rizvi, A | 1 |
| Quadri, F | 1 |
| Tipoo, FA | 1 |
| Khurshid, M | 1 |
| Sajjad, Z | 1 |
| Colan, S | 1 |
| Hasan, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study[NCT02065492] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amlodipine and Thalassemia
| Article | Year |
|---|---|
Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Humans; Iron; Iron Chelating Agents; Iron Ov | 2023 |
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Topics: Amlodipine; beta-Thalassemia; Humans; Iron Chelating Agents; Iron Overload; Thalassemia | 2021 |
2 trials available for amlodipine and Thalassemia
| Article | Year |
|---|---|
Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Chelation Therapy; Child; Ferritins; Humans; | 2022 |
Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.
Topics: Adolescent; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiomyopathies; Chelat | 2014 |